General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Trend Tracker for (VCNX) | news.google.com • |
VCNX Stock Earnings: Vaccinex Reported Results for Q1 2024 | news.google.com • |
VCNX Stock Earnings: Vaccinex Reported Results for Q1 2024 | news.google.com • |
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update | globenewswire.com • |
Vaccinex Reports 2023 Financial Results and Provides Corporate Update | globenewswire.com • |
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules | globenewswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-15 | 2024-03 | 0 | -2.94 | N/A | N/A |
2024-04-02 | 2023-12 | 0 | -39.4 | N/A | N/A |
2023-11-13 | 2023-09 | 0 | -15.27 | N/A | N/A |
2023-08-14 | 2023-06 | 0 | -25.2 | N/A | N/A |
2023-05-15 | 2023-03 | 0 | -21 | N/A | N/A |
2023-04-03 | 2022-12 | 0 | -23.1 | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-08-12 | ANTIBODY INVESTMENTS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
2022-11-22 | FRIEBERG JACOB B | Director | 0.00 | Stock Award(Grant) |
2024-02-07 | FRIEDBERG ALBERT D | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
2020-07-26 | LEONARD JOHN E | Officer | 2.01K | Conversion of Exercise of derivative security |
2020-09-02 | ROYER SCOTT E | Chief Financial Officer | 4.50K | Conversion of Exercise of derivative security |
2023-12-25 | VAN STRYDONCK GERALD E | Director | 0.00 | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | AIGH Capital Management LLC | 90.17K | 481.52K | 0.14% |
2023-06-29 | Vanguard Group Inc | 48.86K | 260.90K | 0.07% |
2022-12-30 | Telemetry Investments, L.L.C. | 27.73K | 268.11K | 0.04% |
2023-06-29 | Geode Capital Management, LLC | 16.68K | 89.07K | 0.03% |
2023-06-29 | Citadel Advisors Llc | 6.87K | 36.70K | 0.01% |
2023-06-29 | State Street Corporation | 4.76K | 25.42K | 0.01% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 35.63K | 190.28K | 0.05% |
2023-05-30 | Fidelity Extended Market Index Fund | 10.94K | 66.50K | 0.02% |
2023-06-29 | Vanguard Extended Market Index Fund | 12.59K | 67.22K | 0.02% |
Split | Date |
---|---|
1 : 14 | 2024-02-20 |
1 : 15 | 2023-09-26 |
Vaccinex Inc Announces Reverse Stock Split and Equity Adjustments
Vaccinex Inc Announces Reverse Stock Split and Equity Adjustments
Vaccinex Inc (VCNX) has released an update.
On February 14, 2024, Vaccinex, Inc. implemented a 1-for-14 reverse stock split, consolidating every fourteen shares into one. This adjustment, effective on February 19, aims to maintain proportional shareholder interests, adjusting equity incentive plans accordingly, without changing stock par value or shareholders’ voting rights. The stock will trade under the same symbol “VCNX” with a new CUSIP number starting February 20 on Nasdaq. Despite these changes, the company cautions that forward-looking statements involve risks and actual results may vary.
For further insights into VCNX stock, check out TipRanks’ Stock Analysis page.
Taco taco
Taco 3.5million insider buying on insider tab. Bull
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
Anthx, Nvda, vcnx
Vcnx 3.5 million insider buys, Amd, Nvidia, axon, Webl, Soxl, Unh, bug
Vcnx 3.5 million insider buys, Amd, Nvidia, axon, Webl, Soxl, Unh
I am lfg
Vcnx, Nividia, Amd, Soxl, Webl, axon, oil
3.5 million in insider buys. Big news coming
These are the prices for later today. Come on now don’t be scared buy.
I am LFG.
Check insider buying
Who buys 3.5 million to piss it away
The day is the day when big news comes
Just waiting on the news, 3.5 million bought, something big coming.
Taco taco taco round two
That was the point
Still here. Cheers